EANS-News: Epigenomics AG Receives Allowance of Key Patent in the U.S.

Patent covers detection of colorectal cancer with Septin9 Biomarker

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Patents, Copyright & Trademarks/Molecular diagnostics

Subtitle: Patent covers detection of colorectal cancer with Septin9
Biomarker

Press release, Berlin, Germany, and Seattle, WA, USA, April 27, 2010
(euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), a
cancer molecular diagnostics company, today announced that it has
received a "Notice of Allowance" notification stating that the United
States Patent and Trademark Office intends to grant a patent for
Epigenomics' Septin9 DNA methylation biomarker (mSEPT9). The company
received the grant of the corresponding patent in Europe in 2008. The
application for which Epigenomics received the Notice of Allowance
covers a method for the detection or classification of colorectal
cancer by means of the DNA methylation status of the Septin9 gene.

Septin9 is at the core of the Epi proColon product, Epigenomics' in
vitro diagnostic blood test for early detection of colorectal cancer.
The test is based on the detection of methylated Septin9 DNA (mSEPT9)
in blood. This epigenetic modification of the Septin9 gene can be
detected in the vast majority of tumors in the colon and rectum. As
tumors shed DNA into the bloodstream, the detection of circulating
methylated Septin9 DNA with the sensitive Epi proColon assay is a
reliable indicator of acute colorectal cancer. In October 2009 Epi
proColon has been introduced as a CE-marked in vitro diagnostic
product in Europe.

Following the receipt of the patent allowance Geert Nygaard, CEO of
Epigenomics, commented: "Receiving the grant of the Septin9 patent in
the U.S. significantly strengthens our intellectual property
portfolio. We now have patents covering the Septin9 biomarker in our
colorectal cancer screening business in Europe as well as the U.S.
This strong patent position for diagnostic content is at the heart of
our business model and we leverage this asset in our deals with
diagnostic industry partners such as Abbott, Sysmex, Quest and ARUP
as well as direct commercialization in certain market segments."

Dr. Andrew Sledziewski, Senior Vice President of Research at
Epigenomics added: "The Septin9 patent is one of multiple biomarker
patent applications we have filed over the past several years
covering novel DNA methylation biomarkers in many cancer indications.
The current Notice of Allowance further validates the innovative
nature of our Septin9 colorectal cancer blood test and underscores
our company's leadership in molecular diagnostics based on DNA
methylation."

About Epi pro Colon

Epi proColon is Epigenomics' CE-marked, in vitro diagnostic real-time
PCR test kit for the qualitative detection of Septin9 gene
methylation in cell-free bisulfite converted DNA isolated from human
plasma samples. Presence of methylated Septin9 DNA is associated
with, and may aid in the detection of, invasive colorectal
adenocarcinoma.

For more information on the Epi proColon test and its availability
and distribution options in Europe please visit www.epiprocolon.com
or contact Epigenomics directly by Email
sales@products.epigenomics.com or phone +49 30 24345 111.

Epi proColon is not for sale in the United States of America. The
analytical and clinical performance characteristics of the product
have not been evaluated by the US Food and Drug Administration. The
product is CE-marked in compliance with the European IVD Directive
98/79/EC.

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests on the market and in development aim
at diagnosing cancer at an early stage before symptoms occur and
thereby may reduce mortality from this dreaded disease.

Epigenomics' product portfolio contains the CE-marked IVD test Epi
proColon, the world's first regulatory cleared molecular diagnostic
test for the detection of colorectal cancer in blood that is based on
the biomarker Septin9, and further proprietary DNA methylation
biomarkers and IVD products at various stages of development for
colorectal, lung and prostate cancer. For development and global
commercialization of IVD test products, Epigenomics pursues a dual
business strategy in which direct commercialization of proprietary
diagnostic test products is combined with non-exclusive licensing to
diagnostic industry players with broad customer access. Strategic
diagnostics industry partners include Abbott Molecular, Sysmex
Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories,
Inc. for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary,
Epigenomics Inc., in Seattle, WA, U.S.A. For more information, please
visit Epigenomics' website at www.epigenomics.com

Epigenomics legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale in the
United States. The analytical and clinical performance
characteristics of any product based on this technology which may be
sold at some future time in the U.S. have not been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade